What Stocks to Buy Today: 7 Picks in Tech, Robotics, and Biotech

If you're wondering what stocks to buy today, you've come to the right place.

You see, every day our Money Morning experts deliver the best stocks to buy across a range of sectors. Then each week we collect the latest recommendations in one roundup, in case you missed any.

Last week Money Morning Biotech Investing Specialist Ernie Tremblay revealed the best stock to profit from the $20 billion-per-year weight loss industry.

Tech Specialist Michael A. Robinson offered the best way to cash in on a $15 billion subsector of the greater automotive tech industry.

Chief Investment Strategist Keith Fitz-Gerald discussed a micro-cap stock he projects will soar more than 1,000% in five years - but you'll have to get in now to benefit from the "first mover" advantage.

And there's much more. You can find all of last week's recommendations here in our newest list showcasing what stocks to buy today.

What Stocks to Buy Today: 7 New Picks

• Two-thirds of adults and one-third of children in the United States are overweight or obese. But despite those statistics, and the known health risks associated with obesity, weight loss (or "bariatric") drugs face many obstacles in finding their way to the patients who need them. Not only must these drugs pass through the FDA approval gauntlet, but doctors must be willing to prescribe them and insurance companies willing to cover them. And because every weight loss drug in the past was eventually pulled from the shelves due to unwanted or even dangerous side effects, the FDA has been slow to approve new ones. But Money Morning Biotech Investing Specialist Ernie Tremblay believes a recently approved drug will be a game-changer for the $20-billion-a-year weight loss industry. Post-approval studies revealed the drug causes a wide array of positive cardiovascular effects. Shares of the company that makes the drug have already risen more than 50% in the last two months. But Tremblay predicts even bigger gains ahead for the biotech firm behind what could be "one of the biggest medical blockbusters of all time"...

• Money Morning Tech Specialist Michael A. Robinson believes we're on the verge of "mass adoption" for what's known as advanced driver assistance systems (ADAS). Although this technology won't yet achieve truly driverless automobiles, it does result in cars that can steer, brake, and accelerate on their own. So in the near future, look for luxury autos to offer safety features such as lane control, collision avoidance, and self-braking. The federal government will likely begin requiring some of these features in all new vehicles in five years or so, bringing this technology one step closer to the masses. In 2013, the ADAS market was worth $14.8 billion, according to Transparency Market Research. But that figure could more than triple to $50.4 billion by the end of the decade. Robinson shared with Money Morning Members the best way to profit from this market's growth. The company is a leader in collision-avoidance technology. It's partnering with at least 15 global automakers. And Robinson predicts its stock will double in less than three years...

• Last October, Money Morning Chief Investment Strategist Keith Fitz-Gerald recommended a tiny, then under-the-radar company that makes the very best wearable robotics suits for people with severe mobility disorders. Its stock was trading at just $1 a share, but Fitz-Gerald predicted it would zoom all the way to $21.14 by 2020. He's remained bullish on the stock ever since, despite occasional volatility, which is normal for a company of its size. Now, on the heels of an outstanding earnings report in March, in which revenue increased 87.5% from the year-ago quarter, not one but two old-line investing firms have initiated coverage of the stock with a "Buy" rating. Fitz-Gerald says this means the "dam of institutional interest" has been broken. Now the stock has almost doubled since he first recommended it. He recently upped his target to $21.85 by 2020 - a 1,020% increase from the current share price. But if you want to get in on these incredible gains, you'll need to act quickly...

• Uranium has been one of the worst-performing commodities markets for years. The 2011 Fukushima nuclear disaster and subsequent shutdown of 54 of Japan's reactors reduced world demand for uranium by 10%. Since then, prices have fallen by more than half. But Money Morning Resource Specialist Peter Krauth says uranium is heading for a rebound, as supply dwindles and demand surges. Japan is gradually returning to nuclear power. And globally there are hundreds of new reactors under construction or in the planning stages. Meanwhile, many uranium mines have shut down completely or scaled back operations due to falling prices. And bans on uranium mining in certain parts of Australia and Canada are further hampering supply. Spot uranium currently trades at $39 per pound, up from $28 in mid-2014. But analysts estimate a price of $83 per pound is required to support new production of uranium from conventional mining projects. Krauth shared the best and most low-risk way to play uranium's rebound...

[epom key="ddec3ef33420ef7c9964a4695c349764" redirect="" sourceid="" imported="false"]

• With the growth of China's economy slowing, Wall Street is growing wary of investing in the nation. But according to Chief Investment Strategist Keith Fitz-Gerald, "The only thing Western analysts calling for China's demise have been for the last 40 years is wrong." Despite slowing growth, China still has the largest population and is on track to become the world's largest economy. And two China exchange-traded funds (ETFs) offer the best way to play this emerging Asian market. One provides a very liquid, heavily traded fund for investors who want easy entry with a broad market play. The other has a narrower focus on a booming sector with a huge windfall coming its way. Get both picks here to start profiting now, while other Western investors are busy running in the other direction...

• The Greek debt crisis won't end well. Greece can't repay its debts, so the crisis will only end in a default or a Greek exit from the Eurozone. Both outcomes would have dire implications for the Eurozone - but European markets don't seem too concerned about that right now. The EuroStoxx 600, a broad Eurozone market index, is up 21% so far this year. It's traded up near 15-year highs. Instead of the Greek debt debacle, the focus has been on the European Central Bank's 60 billion euro ($66.2 billion) a month bond-buying program. As the European markets surge, investors have a unique opportunity to benefit from the upside in European stocks and a potential short-term rise in the euro. But you have to get in now. Here's how to do it...

Bonus: The best gold "stocks" to buy right now aren't exactly stocks. But they do let you essentially buy gold at a discount. Here are two great picks...